Submissions from 2023
A Rare Case of Demodicosis Following Treatment With Oral Fluconazole., Joshua A Bezecny, Emily Bolton, Matthew H Taylor, and Elizabeth G Berry
Cancer's Dark Matter: Lighting the Abyss Unveils Universe of New Therapies., Bernard A Fox, Walter J Urba, Shawn M Jensen, David B Page, Brendan D Curti, Rachel E Sanborn, and Rom S Leidner
SALVO: Single Arm Trial of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma., Lisa A Kottschade, Gregory Russell Pond, Anthony J Olszanski, Yousef Zakharia, Evidio Domingo-Musibay, Ralph J Hauke, Brendan Curti, Sarah Schober, Mohammed M Milhem, Matthew S Block, Tina Hieken, and Robert R McWilliams
Lorigerlimab, a bispecific PD-1×CTLA-4 DART molecule in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): A phase 1 expansion (exp) cohort., Jason J. Luke, Rachel E Sanborn, and See full list of authors in comments
Tumor resident memory CD8 T cells and concomitant tumor immunity develop independently of CD4 help., Terry R Medler, Gwen Kramer, Shelly Bambina, Andrew J Gunderson, Alejandro Alice, Tiffany Blair, Lauren Zebertavage, Thomas Duhen, Rebekka Duhen, Kristina Young, Marka R Crittenden, and Michael J Gough
Multicenter International Study of the Consensus Immunoscore for the Prediction of Relapse and Survival in Early-Stage Colon Cancer., Bernhard Mlecnik, Alessandro Lugli, Gabriela Bindea, Florence Marliot, Carlo Bifulco, Jiun-Kae Jack Lee, Inti Zlobec, Tilman T Rau, Martin D Berger, Iris D Nagtegaal, Elisa Vink-Börger, Arndt Hartmann, Carol I Geppert, Julie Kolwelter, Susanne Merkel, Robert Grützmann, Marc Van den Eynde, Anne Jouret-Mourin, Alex Kartheuser, Daniel Léonard, Christophe Remue, Julia Wang, Prashant Bavi, Michael H A Roehrl, Pamela S Ohashi, Linh T Nguyen, SeongJun Han, Heather L MacGregor, Sara Hafezi-Bakhtiari, Bradly G Wouters, Giuseppe V Masucci, Emilia K Andersson, Eva Zavadova, Michal Vocka, Jan Spacek, Lubos Petruzelka, Bohuslav Konopasek, Pavel Dundr, Helena Skalova, Kristyna Nemejcova, Gerardo Botti, Fabiana Tatangelo, Paolo Delrio, Gennaro Ciliberto, Michele Maio, Luigi Laghi, Fabio Grizzi, Tessa Fredriksen, Bénédicte Buttard, Lucie Lafontaine, Pauline Maby, Amine Majdi, Assia Hijazi, Carine El Sissy, Amos Kirilovsky, Anne Berger, Christine Lagorce, Christopher Paustian, Carmen Ballesteros-Merino, Jeroen Dijkstra, Carlijn van de Water, Shannon van Lent-van Vliet, Nikki Knijn, Ana-Maria Mușină, Dragos-Viorel Scripcariu, Boryana Popivanova, Mingli Xu, Tomonobu Fujita, Shoichi Hazama, Nobuaki Suzuki, Hiroaki Nagano, Kiyotaka Okuno, Toshihiko Torigoe, Noriyuki Sato, Tomohisa Furuhata, Ichiro Takemasa, Prabhu Patel, Hemangini H Vora, Birva Shah, Jayendrakumar B Patel, Kruti N Rajvik, Shashank J Pandya, Shilin N Shukla, Yili Wang, Guanjun Zhang, Yutaka Kawakami, Francesco M Marincola, Paolo A Ascierto, Bernard A Fox, Franck Pagès, and Jérôme Galon
Novel Directions of ADCs in Breast Cancer. Binaytara Foundation Highlights from SABCS 2022; 2023 January 20; Seattle, WA., David B Page
Screening for occult cancer after unprovoked venous thromboembolism: Assessing the current literature and future directions., Sarah S Patel, Derrick Tao, Hannah S McMurry, and Joseph J Shatzel
A phase Ib study of interleukin-2 plus pembrolizumab for patients with advanced melanoma., Ann W Silk, Brendan Curti, Jennifer Bryan, Tracie Saunders, Weichung Shih, Michael P Kane, Phoebe Hannon, Christopher B Fountain, Jessica Felcher, Andrew Zloza, Howard L Kaufman, Janice M Mehnert, and David F McDermott
Developments in Checkpoint Inhibitor Therapy for the Management of Deficient Mismatch Repair (dMMR) Rectal Cancer., Alan Su, Rodrigo Pedraza, and Hagen F Kennecke
T Cell Agonists. SITC Winter School Annual Meeting; 2023 January 18; Austin, TX., Andrew D Weinberg
Disruption of the MYC Super-Enhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia., William M Yashar, Brittany M Curtiss, Daniel J Coleman, Jake VanCampen, Garth Kong, Jommel Macaraeg, Joseph Estabrook, Emek Demir, Nicola Long, Daniel Bottomly, Shannon K McWeeney, Jeffrey W Tyner, Brian J Druker, Julia E Maxson, and Theodore P Braun
Submissions from 2022
A phase 1 multiple-ascending dose study to evaluate the safety and tolerability of XmAb23104 (PD-1 x ICOS) in subjects with selected advanced solid tumors (DUET-3)., Mehmet Akce, Rom Leidner, and See full list of authors in comments
Enhancement of anti-tumor efficacy of immune checkpoint blockade by alpha-tocopheryloxacetic acid-lysine, Emmanuel Akporiaye, William L. Redmond, and Melissa Kasiewicz
940 siRNA screen of upregulated genes identifies targets for a multiantigen polyepitope vaccine to prevent HNSCC, Fnu Alka, James Annis, Brady Bernard, and Sasha Stanton
Gut microbiota analyses of Saudi populations for type 2 diabetes-related phenotypes reveals significant association., Fahad A Al-Muhanna, Alexa K Dowdell, Abdulmohsen H Al Eleq, Waleed I Albaker, Andrew W Brooks, Ali I Al-Sultan, Abdullah M Al-Rubaish, Khaled R Alkharsah, Raed M Sulaiman, Abdulaziz A Al-Quorain, Cyril Cyrus, Rudaynah A Alali, Chittibabu Vatte, Fred L Robinson, Xin Zhou, Michael P Snyder, Afnan F Almuhanna, Brendan J Keating, Brian D. Piening, and Amein K Al-Ali
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd - 4th, 2021, Italy)., Paolo A Ascierto, Sanjiv S Agarwala, Christian Blank, Corrado Caracò, Richard D Carvajal, Marc S Ernstoff, Soldano Ferrone, Bernard A Fox, Thomas F Gajewski, Claus Garbe, Jean-Jacques Grob, Omid Hamid, Michelle Krogsgaard, Roger S Lo, Amanda W Lund, Gabriele Madonna, Olivier Michielin, Bart Neyns, Iman Osman, Solange Peters, Poulikos I Poulikakos, Sergio A Quezada, Bradley Reinfeld, Laurence Zitvogel, Igor Puzanov, and Magdalena Thurin
Perspectives in Immunotherapy: meeting report from the Immunotherapy Bridge, December 1st-2nd, 2021., Paolo A Ascierto, Antonio Avallone, Nina Bhardwaj, Carlo Bifulco, Sergio Bracarda, Joshua D Brody, Luigi Buonaguro, Sandra Demaria, Leisha A Emens, Robert L Ferris, Jérôme Galon, Samir N Khleif, Christopher A Klebanoff, Tamara Laskowski, Ignacio Melero, Chrystal M Paulos, Sandro Pignata, Marco Ruella, Inge Marie Svane, Janis M Taube, Bernard A Fox, Patrick Hwu, and Igor Puzanov
The "Great Debate" at Immunotherapy Bridge 2021, December 1st-2nd, 2021., Paolo A Ascierto, Lisa H Butterfield, Olivera J Finn, Andrew Futreal, Omid Hamid, Theresa LaVallee, Michael A Postow, Igor Puzanov, Jeffrey Sosman, Bernard A Fox, and Patrick Hwu
Clinical actionability and therapy selection for advanced NSCLC patients tested using comprehensive genomic profiling, B Bapat, R Weerasignhe, R Meng, A Dowdell, SC Chang, B Schroeder, C Bifulco, and B Piening
Enhancing clinical genomics datasets with multimodal EHR data and imaging, Carlo Bifulco
Lightning talks: AI in healthcare, Carlo Bifulco
Spatial Biology: a Cambrian Explosion of Technology, Carlo Bifulco
The virtual molecular tumor board as a tool for integrating omics in the delivery of precision oncology, Carlo Bifulco
A Random Forest Genomic Classifier for Tumor Agnostic Prediction of Response to Anti-PD1 Immunotherapy., Emma Bigelow, Suchi Saria, Brian D. Piening, Brendan Curti, Alexa K Dowdell, Roshanthi Weerasinghe, Carlo Bifulco, Walter Urba, Noam Finkelstein, Elana J Fertig, Alex Baras, Neeha Zaidi, Elizabeth Jaffee, and Mark Yarchoan
Fluorescence tagging to monitor CD8 T cell recirculation from the tumor to the tumor-draining lymph node: the impact of focal radiation therapy on recirculation, TC Blair, Brian D. Piening, Marka R Crittenden, Michael J. Gough, and See full list of authors in comments
ICOS is upregulated on T cells following radiation and agonism combined with radiation results in enhanced tumor control., Tiffany Blair, Jason Baird, Shelly Bambina, Gwen Kramer, Monica Gostissa, Christopher J Harvey, Michael J Gough, and Marka R Crittenden
Fluorescent tracking identifies key migratory dendritic cells in the lymph node after radiotherapy., Tiffany Blair, Shelly Bambina, Gwen Kramer, Alexa K Dowdell, Alejandro F Alice, Jason R Baird, Amanda W Lund, Brian D. Piening, Marka R Crittenden, and Michael J. Gough
Praluzatamab ravtansine, a CD166-targeting antibody-drug conjugate, in patients with advanced solid tumors: an open-label phase 1/2 trial., Valentina Boni, Mary J Fidler, Hendrik-Tobias Arkenau, Alexander Spira, Funda Meric-Bernstam, Nataliya Uboha, Rachel E Sanborn, Randy F Sweis, Patricia LoRusso, Misako Nagasaka, Javier Garcia-Corbacho, Shadia Jalal, James J Harding, Stella K Kim, Iris H C Miedema, Danielle J Vugts, Marc C Huisman, Gerben J C Zwezerijnen, Guus A M S van Dongen, Catharina W Menke-van der Houven van Oordt, Song Wang, Tam Dang, Ivan A Zein, Olga Vasiljeva, Susan K Lyman, Virginia Paton, Alison Hannah, and Joyce F Liu
997 T cell immunotherapies trigger neutrophils to eliminates heterogenous tumors, Sadna Budha, Rebekka Duhen, Andrew Weinberg, and See all authors in comments
Changes in T-cell subsets and clonal repertoire during chemoimmunotherapy with pembrolizumab and paclitaxel or capecitabine for metastatic triple-negative breast cancer., Brie Chun, Joanna Pucilowska, Shu-Ching Chang, Isaac Kim, Benjamin Nikitin, Yoshinobu Koguchi, William L. Redmond, Brady Bernard, Venkatesh Rajamanickam, Nathan Polaske, Paul A Fields, Valerie Conrad, Mark Schmidt, Walter Urba, Alison Conlin, Heather L McArthur, and David B Page
CT243 / 4 - Phase 1 study of TAK-676 + pembrolizumab following radiation therapy in patients with advanced non-small-cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), or squamous-cell carcinoma of the head and neck (SCCHN), Benjamin Cooper, David B Page, and See full list of authors in comments
For Ethical Fundraising from Patients, Respect them as Partners., Brendan Curti
Chapter 72: Cancer of the Skin, Brendan Curti, Sancy Leachman, and Walter Urba
Dose escalation of davoceticept, a conditional CD28 costimulator and dual checkpoint inhibitor, in advanced malignancies (NEON-1), Diwakar Davar, Rachel E Sanborn, and See full list of authors in comments
Phase 1 study of SEA-TGT, a human, nonfucosylated monoclonal antibody directed to TIGIT with enhanced immune effector function, in patients with advanced malignancies (SGNTGT-001, trial in progress), D Davar, Rachel E Sanborn, and See full list of authors in comments
546 A phase I dose escalation study of STEMVAC, a multi-antigen, multi-epitope Th1 selective plasmid-based vaccine, targeting stem cell associated proteins in patients with advanced breast cancer, Mary Disis, Sasha Stanton, and See all authors in comments
Automatic Patient Matching for Genome-Guided Adoptive Cell Immunotherapy Trials at a Large Health System, Alexa K Dowdell, Tucker Bower, Benjamin Cosgrove, Roshanthi Weerasinghe, Ann Vita, Brian D. Piening, Carlo Bifulco, Eric Tran, and Rom Leidner
OX40 agonist stimulation increases and sustains humoral and cell-mediated responses to SARS-CoV-2 protein and saRNA vaccines., Rebekka Duhen, Michael Beymer, Shawn M. Jensen, Srinivas Abbina, Suraj Abraham, Nikita Jain, Anitha Thomas, Andrew J Geall, Hong-Ming Hu, Bernard A Fox, and Andrew D Weinberg
PD-1 and ICOS co-expression identifies tumor-reactive CD4 T cells in human solid tumors., Rebekka Duhen, Olivier Fesneau, Kimberly Samson, Alexandra K Frye, Michael Beymer, Venkatesh Rajamanickam, David Ross, Eric Tran, Brady Bernard, Andrew D Weinberg, and Thomas Duhen
OX40 boosts and sustains humoral and cellular immune responses to SARS-CoV-2 spike protein and RNA vaccinations, R Duhen, Bernard A Fox, Andrew D Weinberg, and See all authors in comments
PD-1 and ICOS co-expression identifies tumor-reactive CD4 T cells in human solid tumors, Thomas Duhen
Real-world burden of chemotherapy-induced myelosuppression in patients with small cell lung cancer: a retrospective analysis of electronic medical data from community cancer care providers., Robert S. Epstein, Roshanthi Weerasinghe, Amy S. Parrish, JoAnn Krenitsky, Rachel E Sanborn, and Tehseen Salimi
T Cells Engineered to Express Immunoreceptors Targeting the Frequently Expressed Medullary Thyroid Cancer Antigens Calcitonin, CEA, and RET M918T., Timothy A Erickson, Yi-Ping Shih, Joseph Fass, Myungkyu Jang, and Eric Tran
A Phase II, Single-arm Trial of Sunitinib and Erlotinib in Advanced Renal Cell Carcinoma., Zizhen Feng, Brendan Curti, David I Quinn, John M Strother, Zunqiu Chen, Rebecca Agnor, Tomasz M Beer, and Christopher W Ryan
Phase II Randomized Trial of Transoral Surgery and Low-Dose Intensity Modulated Radiation Therapy in Resectable p16+ Locally Advanced Oropharynx Cancer: An ECOG-ACRIN Cancer Research Group Trial (E3311)., Robert L Ferris, Yael Flamand, Gregory S Weinstein, Shuli Li, Harry Quon, Ranee Mehra, Joaquin J Garcia, Christine H Chung, Maura L Gillison, Umamaheswar Duvvuri, Bert W O'Malley, Enver Ozer, Giovana R Thomas, Wayne M Koch, Neil D Gross, Richard Bryan Bell, Nabil F Saba, Miriam Lango, Eduardo Méndez, and Barbara Burtness
Identification of a subset of tumor-reactive CD8 TIL expressing NKG2A in HNSCC and CRC, O Fesneau, K Samson, V Rajamanickam, D Ross, and Thomas Duhen
Combining 10x scRNA-seq and 100 plex mIF: Too much data or complimentary technologies to examine what works, Bernard Fox
Recommended phase 2 dose (RP2D) of HB-200 arenavirus-based cancer immunotherapies in patients with HPV16+ cancers., Siqing Fu, Rom Leidner, and Matthew H Taylor
A phase 2 study of an off-the-shelf, multi-neoantigen vector (ADXS-503) in patients with metastatic non–small cell lung cancer either progressing on prior pembrolizumab or in the first-line setting., Gregory James Gerstner, Rachel E Sanborn, and See full list of authors in comments
A phase 1b, multicenter, dose-escalation study of subasumstat (TAK-981) in combination with pembrolizumab in patients (pts) with advanced solid tumors., Sanjay Goel, Rachel E Sanborn, and See full list of authors in comments
Safety and tolerability of MEDI0562, an OX40 agonist monoclonal antibody, in combination with durvalumab or tremelimumab in adult patients with advanced solid tumors., Jonathan W Goldman, Sarina A Piha-Paul, Brendan Curti, Katrina S Pedersen, Todd M Bauer, Stefanie L Groenland, Richard D Carvajal, Vaishali Chhaya, Gray Kirby, Kelly McGlinchey, Scott A Hammond, Katie L Streicher, Danielle Townsley, Young Kwang Chae, Jens Voortman, Aurelien Marabelle, and John Powderly
Fluorescence tagging to monitor CD8 T cell recirculation from the tumor to the tumor-draining lymph node: the impact of focal radiation therapy on recirculation, Michael J. Gough
Tumor resident memory CD8 T cell formation and concomitant tumor immunity is CD40L dependent and CD4 independent, Michael J. Gough
The paradox of radiation and T cells in tumors., Michael J. Gough and Marka R Crittenden
Durability of B and T cell responses against a spike protein of SARS-CoV2 elicited by mRNA vaccines, LT Hamilton, Bernard A Fox, William L. Redmond, Brian D. Piening, and See full list of authors in comments
5 Development of a vaccine to intercept oral cancer, Traci Hilton, Tarsem Moudgil, Richard Bryan Bell, and See all authors in comments
731 A first-in-human trial of an integrin beta-6 targeted antibody-drug conjugate (ADC), SGN-B6A, in patients with advanced solid tumors: interim results of a phase 1 study (SGNB6A-001), Antoine Hollebecque, Rachel E Sanborn, and See full list of authors in comments
8 Universal LCMS-based assay platform, refmAb-Q nSMOL, for monitoring monoclonal antibody therapeutics using one reference antibody, Noriko Iawmoto, Yoshinobu Koguchi, Kotoko Yokoyama, Akinobu Hamada, Atsushi Yonezawa, Brian Piening, Eric Tran, Bernard Fox, William Redmond, and Takashi Shimada
Proteogenomic Characterization of Head and Neck Squamous Cell Cancer Immunopeptidomes to Detect Non Canonical Protein Targets for Cancer Immunotherapy., N Iwamoto, Richard Bryan Bell, Carlo Bifulco, Walter Urba, Rom Leidner, Brian D. Piening, Bernard A Fox, and See full author list in comments
A rapid and universal liquid chromatograph-mass spectrometry-based platform, refmAb-Q nSMOL, for monitoring monoclonal antibody therapeutics., Noriko Iwamoto, Yoshinobu Koguchi, Kotoko Yokoyama, Akinobu Hamada, Atsushi Yonezawa, Brian D Piening, Eric Tran, Bernard A Fox, William L Redmond, and Takashi Shimada
Mid-pregnancy immune dysregulation and its association with maternal metabolic and genetic factors in those with preterm birth: Insights using artificial intelligence., L Jelliffe-Pawlowski, Brian D. Piening, and See full list of authors in comments
Interim results of an ongoing phase 1/2a study of HPN328, a tri-specific, half-life extended, DLL3-targeting, T-cell engager, in patients with small cell lung cancer and other neuroendocrine cancers., Melissa Lynne Johnson, Rachel E Sanborn, and See full list of authors in comments
Ex vivo analysis of radiation effects on tumor infiltrating immune cells using tumor explants, Aanchal Preet Kaur, Gwen Kramer, Marka R. Crittenden, and Michael J. Gough
Neoadjuvant Chemotherapy, Excision, and Observation for Early Rectal Cancer: The Phase II NEO Trial (CCTG CO.28) Primary End Point Results., Hagen F Kennecke, Chris J O'Callaghan, Jonathan M Loree, Hussein Moloo, Rebecca Auer, Derek J Jonker, Manoj Raval, Reilly Musselman, Grace Ma, Antonio Caycedo-Marulanda, Vlad V Simianu, Sunil Patel, Lacey D Pitre, Ramzi Helewa, Vallerie L Gordon, Katerina Neumann, Halla Nimeiri, Max Sherry, Dongsheng Tu, and Carl J Brown
O006/#1066 Randomized trial of pelvic radiation with and without concurrent cisplatin in patients with a pelvic only recurrence of endometrial cancer, Ann Klopp, Christopher Darus, and See all authors in comments
A Novel Class of On-Treatment Cancer Immunotherapy Biomarker: Trough Levels of Antibody Therapeutics in Peripheral Blood., Yoshinobu Koguchi and William L Redmond
Factors impacting genomic testing rates among epithelial ovarian cancer patients across a large community-based healthcare system (595), Nicole Kretzer, Christopher J. Darus, Nancy Biery, Roshanthi Weerasinghe, Hsin-Fang Li, Ann Vita, Shwetha Pindikuri, Amy Parrish, Charles Drescher, and Fernanda Musa
Frequency of homologous recombination deficiency in a large community-based cohort of epithelial ovarian cancer cases (597), Nicole Kretzer, Fernanda Musa, Christopher Darus, Nancy Biery, Roshanthi Weerasinghe, Hsin-Fang Li, Ann Vita, Shwetha Pindikuri, Amy Parrish, and Charles Drescher
1473 Mechanism of action of bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) in patients with unresectable or metastatic melanoma from the phase 3 randomized open-label PIVOT IO-001 clinical trial, Celeste Lebbe, Brendan Curti, Matthew Taylor, and See all authors in comments
Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer., Rom Leidner, Nelson Sanjuan Silva, Huayu Huang, David Sprott, Chunhong Zheng, Yi-Ping Shih, Amy Leung, Roxanne Payne, Kim Sutcliffe, Julie Cramer, Steven A Rosenberg, Bernard A Fox, Walter Urba, and Eric Tran
CT502 - Preliminary immunological monitoring of first-in-human immunotherapy-trio for advanced head and neck squamous cell carcinoma, Rom Leidner, Matthew H Taylor, William L. Redmond, Brady Bernard, Richard Bryan Bell, Walter Urba, Carlo Bifulco, Brian D. Piening, Bernard A Fox, and See full authors list in comments
Angiotensin receptor blockade and stereotactic body radiation therapy for early stage lung cancer ARB & SBRT for early stage lung cancer., Lauren T Maloney, Emile Latour, Yiyi Chen, Douglas Rice, Alison Grossblatt-Wait, Nima Nabavizadeh, Charles R Thomas, Kristina H Young, Joshua M Walker, John Holland, and Aaron J Grossberg
Neoadjuvant HER2-targeted therapy +/- immunotherapy with pembrolizumab (neoHIP): An open-label randomized phase II trial., Heather L. McArthur, David B. Page, and See all authors in comments
A single-arm, phase 2 study of perioperative ipilimumab, nivolumab, and cryoablation in women with hormone receptor-negative, HER2-negative, early-stage/resectable breast cancer., Heather L. McArthur, David B Page, and See full list of authors in comments
Neoadjuvant HER2-targeted therapy +/- immunotherapy with pembrolizumab (neoHIP): An open-label randomized phase II trial., Heather L. McArthur, David B Page, and See full list of authors in comments
A Single Arm Phase 2 Study of Peri-Operative Checkpoint-Mediated Immune Therapy and Cryoablation in Women with Hormone Receptor-Negative, HER2-Negative Early Stage/Resectable Breast Cancer, Heather McArthur, David B. Page, Staci Mellinger, Nicole Fredrich, Nicole Moxon, and See all authors in comments
Outcomes by tobacco history in E3311, a phase II trial of transoral surgery (TOS) followed by pathology-based adjuvant treatment in HPV-associated (HPV+) oropharynx cancer (OPC): A trial of the ECOG-ACRIN Cancer Research Group., Ranee Mehra, Richard Bryan Bell, and See full list of authors in comments
Immunological profiling of tumor-infiltrating CD8+ T lymphocytes in primary non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), breast cancer (BCa), and renal cell cancers (RCC)., W Miller, William L. Redmond, and See full list of authors in comments
CT041 - Monotherapy dose escalation of davoceticept (ALPN-202), a conditional CD28 costimulator and dual checkpoint inhibitor, in advanced malignancies (NEON-1), Michael Millward, Rachel E Sanborn, and See full list of authors in comments
Clinical Performance of the Consensus Immunoscore in Colon Cancer in the Asian Population from the Multicenter International SITC Study., Bernhard Mlecnik, Toshihiko Torigoe, Gabriela Bindea, Boryana Popivanova, Mingli Xu, Tomonobu Fujita, Shoichi Hazama, Nobuaki Suzuki, Hiroaki Nagano, Kiyotaka Okuno, Yoshihiko Hirohashi, Tomohisa Furuhata, Ichiro Takemasa, Prabhudas Patel, Hemangini Vora, Birva Shah, Jayendrakumar B Patel, Kruti N Rajvik, Shashank J Pandya, Shilin N Shukla, Yili Wang, Guanjun Zhang, Takayuki Yoshino, Hiroya Taniguchi, Carlo Bifulco, Alessandro Lugli, Jiun-Kae Jack Lee, Inti Zlobec, Tilman T Rau, Martin D Berger, Iris D Nagtegaal, Elisa Vink-Börger, Arndt Hartmann, Carol I Geppert, Julie Kolwelter, Susanne Merkel, Robert Grützmann, Marc Van den Eynde, Anne Jouret-Mourin, Alex Kartheuser, Daniel Léonard, Christophe Remue, Julia Wang, Prashant Bavi, Michael H A Roehrl, Pamela S Ohashi, Linh T Nguyen, SeongJun Han, Heather L MacGregor, Sara Hafezi-Bakhtiari, Bradly G Wouters, Giuseppe V Masucci, Emilia Andersson, Eva Zavadova, Michal Vocka, Jan Spacek, Lubos Petruzelka, Bohuslav Konopasek, Pavel Dundr, Helena Skalova, Kristyna Nemejcova, Gerardo Botti, Fabiana Tatangelo, Paolo Delrio, Gennaro Ciliberto, Michele Maio, Luigi Laghi, Fabio Grizzi, Florence Marliot, Tessa Fredriksen, Bénédicte Buttard, Lucie Lafontaine, Pauline Maby, Amine Majdi, Assia Hijazi, Carine El Sissy, Amos Kirilovsky, Anne Berger, Christine Lagorce, Christopher Paustian, Carmen Ballesteros-Merino, Jeroen Dijkstra, Carlijn Van de Water, Shannon van Lent-van Vliet, Nikki Knijn, Ana-Maria Mușină, Dragos-Viorel Scripcariu, Francesco M Marincola, Paolo A Ascierto, Bernard A Fox, Franck Pagès, Yutaka Kawakami, and Jérôme Galon
CT250 / 11 - A first-in-human phase 1 study of NL-201 in patients with relapsed or refractory cancer, Aung Naing, Brendan Curti, and See full list of authors in comments
The Human Tumor Atlas Network's beginning steps toward the future of collaborative multi-omic discovery., David B Page
Brain radiotherapy, tremelimumab-mediated CTLA-4-directed blockade +/- trastuzumab in patients with breast cancer brain metastases., David B Page, Kathryn Beal, Stefanie N Linch, Kateri Spinelli, Micaela Rodine, Darragh Halpenny, Shanu Modi, Sujata Patil, Robert J Young, Thomas Kaley, Taha Merghoub, David Redmond, Phillip Wong, Christopher A Barker, Adi Diab, Larry Norton, and Heather L McArthur
1296 Radiomics-based multi-modal prediction of treatment response to PD-1/PD-L1 immune checkpoint inhibitor (ICI) therapy in stage IV non-small cell lung carcinoma (mNSCLC), Ravi Parikh, Brendan Curti, Roshanthi Weerasinghe, and See all authors in comments
Chemoradiation therapy alters the PD-L1 score in locoregional recurrent squamous cell carcinomas of the head and neck., Brian J Park, Austin K Mattox, Daniel Clayburgh, Mihir Patel, R Bryan Bell, Bevan Yueh, Rom Leidner, Hong Xiao, Marcus Couey, Shiting Li, Tingting Qin, Maureen A Sartor, Belinda Cairns, Tracy MacDonough, Kyle Halliwill, Daniel Deschler, Derrick T Lin, William C Faquin, Peter M Sadow, and Sara I Pai
Real-World Evidence Insights in Cancer Research and Care, Brian D. Piening
Pathogenic fusion detection in solid malignancies utilizing RNA-DNA based comprehensive genomic profiling (CGP) testing., Brian D. Piening, Alexa K Dowdell, Ryan Meng, Ann Vita, Roshanthi Weerasinghe, Alisha Stein, Bela Bapat, Brock Shroeder, Shu-Ching Chang, Lauren Harold, Mark Schmidt, Thomas R. Ward, Josiah T Wagner, Stanley Piotrowski, Phillip G. Febbo, and Carlo Bifulco
Elucidating Diversity in Obesity-Related Phenotypes Using Longitudinal and Multi-omic Approaches, Brian D. Piening, Alexa K Dowdell, and Michael P. Snyder
Whole transcriptome profiling of prospective endomyocardial biopsies reveals prognostic and diagnostic signatures of cardiac allograft rejection., Brian D. Piening, Alexa K Dowdell, Mengqi Zhang, Bao-Li Loza, David Walls, Hui Gao, Maede Mohebnasab, Yun Rose Li, Eric Elftmann, Eric Wei, Divya Gandla, Hetal Lad, Hassan Chaib, Nancy K Sweitzer, Mario Deng, Alexandre C Pereira, Martin Cadeiras, Abraham Shaked, Michael P Snyder, and Brendan J Keating
Design and Implementation of a Decentralized Virtual Molecular Tumor Board across a Large, Diverse Community Health System, Brian Piening, Patrick Foley, K Matlock, H Wright, Lauren Harold, Roshanthi Weerasinghe, A Viita, C Moung-Wen, Jacob Abel, Vassil Kaimaktchiev, A Dowdell, Ryan Meng, Walter Urba, G Srinivasa, Philip Gold, Gina Vaccaro, and Carlo Bifulco
Epacadostat Plus Pembrolizumab and Chemotherapy for Advanced Solid Tumors: Results from the Phase I/II ECHO-207/KEYNOTE-723 Study., John D Powderly, Samuel J Klempner, Aung Naing, Johanna Bendell, Ignacio Garrido-Laguna, Daniel V T Catenacci, Matthew H Taylor, James J Lee, Fred Zheng, Feng Zhou, Xiaohua Gong, Hema Gowda, and Gregory L Beatty
CT209 / 9 - A first-in-human phase 1 trial of IO-108, an antagonist antibody targeting LILRB2 (ILT4), as monotherapy and in combination with pembrolizumab in adult patients with advanced relapsed or refractory solid tumors (NCT05054348), John Powderly, Matthew H Taylor, and See full list of authors in comments
Multimodal single-cell analysis of human TILs across multiple tumor types reveals heterogeneity and potential opportunities for personalized immunotherapy, William L. Redmond
Novel mechanisms to augment the efficacy of cancer immunotherapy, William L. Redmond
Multimodal single-cell analysis of human tumor infiltrating immune cells across multiple tumor types reveals heterogeneity and potential opportunities for personalized immunotherapeutic strategies., William L. Redmond and See full list of authors in comments
